The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells

Ronald Walls, Alain Thibault, Lei Liu, Chris Wood, James M. Kozlowski, William D. Figg, Maureen L. Sampson, Ronald J. Elin, Dvorit Samid*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

The prostatic-specific antigen (PSA) is the tumor marker most widely relied upon for the monitoring of patients with prostate cancer. Recently, declines in the serum concentrations of PSA have been advocated as a surrogate marker of tumor response in clinical trials of investigational antitumor agents. We examined the hypothesis that this postulate may not apply to the evaluation of drugs such as phenylacetate, a differentiating agent endowed with mechanisms of action different from those of classic cytotoxic chemotherapy. Using human prostatic carcinoma LNCaP cells as a model, we show that phenylacetate induces PSA production despite inhibition of tumor cell proliferation. Incubation of LNCaP cultures with cytostatic doses of phenylacetate (3-10 mM) resulted in a three- to fourfold increase in PSA secretion per cell. This appears to result from upregulation of PSA gene expression, as indicated by elevated PSA mRNA steady-state levels in treated cells. The increase in PSA production per cell was confirmed in rats bearing subcutaneous LNCaP tumor implants that were treated systemically with phenylacetate. Further comparative studies indicate that upregulation of PSA is common to various differentiation inducers, including all-trans-retinoic acid, 1,25-dihydroxyvitamin D3, and butyrate but is not induced by other antitumor agents of clinical interest such as suramin. We conclude that declines in PSA may be treatment specific and that the exclusive use of this criterion as a marker of disease response may mislead the proper evaluation of differentiating agents in prostate cancer patients.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
JournalProstate
Volume29
Issue number3
DOIs
StatePublished - Sep 1 1996

Keywords

  • aromatic fatty acid
  • differentiation therapy
  • tumor markers

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells'. Together they form a unique fingerprint.

Cite this